U.S. Markets open in 7 hrs 23 mins

Audentes Therapeutics Inc (BOLD) Files 10-K for the Fiscal Year Ended on December 31, 2018

- By insider

Audentes Therapeutics Inc (BOLD) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. Audentes Therapeutics Inc is a biotechnology company. It is engaged in developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. Audentes Therapeutics Inc has a market cap of $1.46 billion; its shares were traded at around $34.16 .


CEO Recent Trades:

  • CEO Matthew R Patterson sold 21,000 shares of BOLD stock on 02/25/2019 at the average price of $30. The price of the stock has increased by 13.87% since.

Directors and Officers Recent Trades:

  • Senior VP & Chief Med Officer Suyash Prasad sold 10,000 shares of BOLD stock on 02/25/2019 at the average price of $30.06. The price of the stock has increased by 13.64% since.

For the complete 20-year historical financial data of BOLD, click here.

This article first appeared on GuruFocus.